Back to Newsroom
Back to Newsroom

Alercell Continues to be Resilient in America's COVID-19 Response

Tuesday, March 15, 2022 7:20 PM

BOZEMAN, MT / ACCESSWIRE / March 15, 2022 / Based in Bozeman, Montana, and led by Chief Executive Officer Frederic Sheer, a biotechnology company ALERCELL continues to show resilience in America's fight against COVID-19. Earlier in 2021, the company announced that it will distribute Luminostics' Clip COVID Rapid Antigen Test along with its antigen test collection kits throughout the country. It also announced a $280 million agreement for COVID-19 rapid blood tests, partnering with Medigen Biotechnology Corporation.

Alercell INC., Tuesday, March 15, 2022, Press release picture

"We are pleased to work with Luminostics because of the very high Sensitivity and Specificity of the Clip COVID Rapid Antigen Test. We believe that Luminostics technology is ahead of the competition. This new high-sensitivity antigen test is another example of Alercell 's commitment to providing people with the information they need to make important health decisions," states Dr Alexandre Scheer, Chief Medical Officer of Alercell.

In his previous career as a financial advisor, Alercell, Inc. co-founder Frederic Scheer floated multiple start-up firms on the Bulletin-Board and the NASDAQ. For the past 25 years, he has worked in the chemical business and alternative technology. 15 US biotechnology patents are held by Mr. Scheer. A bioplastics firm called Biocorp, Inc. was formed by him, as was a chemical resin company called Cereplast, Inc., which he listed on the NASDAQ. Mr. Scheer is a graduate of the University of Paris and the Institut d'Etudes Politiques de Paris, where he earned two doctorates in law and an MBA.

ABOUT Alercell, Inc:

Alercell is a Biotechnology company located in Bozeman, Montana. Alercell was founded in 2020 by a group of medical researchers with extensive experience in the field of stem cell research, and the company's primary focus is the development, manufacture, and distribution of an efficient therapy for the Covid-19 pandemic. As a result of this expansion, Alercell wants to offer a wide range of healthcare treatments for infectious disorders.

Media Contact:
Bianca Leon Rodriguez
Phone: +1 (817) 406-8354
Email: [email protected]

SOURCE: Alercell INC.

Company Update
Back to newsroom
Back to Newsroom